Dr. Mittendorf on Cyclin E as a Target in Breast Cancer

Elizabeth Mittendorf, MD, PhD
Published Online: Thursday, August 29, 2013
Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Cyclin E is an important cell cycle regulator, Mittendorf says, and it has been discovered that it can be cleaved into low molecular weight (LMW) isoforms. These LMW isoforms are tumor-specific and cause cells to be less susceptible to inhibition and proliferate through the cell cycle more rapidly.

From a disease standpoint, LMW cyclin E is associated with a poor prognosis, meaning that it could be a target, though this is still be pursued. Mittendorf says that she views cyclin E slightly differently and says that it could be a target for immunotherapy because of its overexpression and abnormal expression in breast cancer.

This preclinical observation has been published and Mittendorf says that a decision needs to be made as to whether or not to pursue cyclin E as a therapeutic strategy.

Online CME Activities
Free CME from PER
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
More Reading
Publications
$auto_registration$